Association of Dysphagia with Significant Esophageal Motility Disorders in the UAE: A Retrospective Analysis from a Tertiary Care Facility in Abu Dhabi - Summary - MDSpire
Advertisement
Association of Dysphagia with Significant Esophageal Motility Disorders in the UAE: A Retrospective Analysis from a Tertiary Care Facility in Abu Dhabi
To assess the relationship between dysphagia and Major Esophageal Motility Disorders (MEMDs) in patients undergoing high-resolution esophageal manometry (HREM) in the UAE, highlighting its significance in the context of existing literature.
Key Findings:
Dysphagia is associated with Major Esophageal Motility Disorders in the UAE, indicating a need for increased awareness among clinicians.
Major Esophageal Motility Disorders are more common in men and UAE nationals, suggesting demographic factors may influence prevalence.
BMI values and Diabetes Mellitus were not associated with the risk of Major Esophageal Motility Disorders in the UAE, differing from findings in other populations.
Interpretation:
The study highlights the significance of dysphagia as a symptom associated with esophageal motility disorders, emphasizing the need for targeted diagnostic approaches in the UAE population and its implications for clinical practice.
Limitations:
Retrospective design may introduce selection bias, and potential confounding factors should be considered.
Limited generalizability due to the specific population studied, which may not represent broader demographics.
Conclusion:
Understanding the association between dysphagia and MEMDs can aid in improving diagnostic accuracy and management strategies for esophageal motility disorders in the UAE, paving the way for future research and clinical guidelines.
by Ameirah Badr Abdullah Al Ali, Laurette L. Bukasa, Tareq Moh’d, Khalifa Saleh Ahmed Al Tenaiji, Mohamed Nasir Alzaabi, Shaima Wasim Khan, Thaer Khaleel Swaid, Hosameldin Abdelrahman Dafalla, Mostafa Ahmed Shehata, Eyad Alakrad
The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.
